- Company
- CMV treatment Livtencity lands in Big 5 hospitals in KOR
- by Eo, Yun-Ho Jan 2, 2024 05:45am
- Livtencity, a cytomegalovirus (CMV) treatment, is nearing prescription at tertiary general hospitals. According to industry sources, Takeda Pharmaceuticals Korea’s Livtencity (maribavir) has recently passed the Drug Committee (DC) of the “Big 5” hospitals, including Seoul National University Hospital, Samsung Seoul Hospital, Seoul St
- Company
- Celltrion merges and launches with founder’s son as leader
- by Kim, Jin-Gu Dec 29, 2023 05:40am
- Celltrion’s Chair of the Board, Jin-Seok Seo, the eldest son of Celltrion’s Chairman Emeritus Jung-jin Seo, will helm the newly merged Celltrion. The new CEO Seo will lead the company in a 3-person representative system with Hyung-Ki Kim, current CEO of Celltrion, and Hyung-Ki Kim, former CEO of Celltrion Healthcare. Celltrion annou
- Company
- K-similars set out to enter the global market
- by Son, Hyung-Min Dec 29, 2023 05:40am
- Domestic companies are now ready to launch homegrown biosimilars into the global market next year. According to industry sources on the 28th, Celltrion, Samsung Bioepis, and Dong-A ST have completed Phase III clinical trials of its biosimilars and applied for approval from overseas regulators. The companies have successfully developed biosimi
- Company
- Integrated Celltrion launches with goal of 40T market cap
- by Kim, Jin-Gu Dec 29, 2023 05:39am
- Celltrion and Celltrion Healthcare are set to launch an integrated corporation. The market capitalization of the integrated Celltrion is expected to reach around 40 trillion won. The launch of the integrated Celltrion is anticipated to unify the previously dispersed biosimilar production and distribution processes. This merger may addre
- Company
- Medytox submits BLA to FDA for its next-gen botulinum
- by Chon, Seung-Hyun Dec 29, 2023 05:39am
- Medytox is working to enter the U.S. market with its next-generation botulinum toxin product, which technology has been reverted to the company after being transferred to a foreign company. On the 27th, Medytox announced that it has filed a biological license application (BLA) to the U.S. Food and Drug Administration (FDA) for its next-gen
- Company
- Hugel Resolves to Retire 371,563 shares of its own stock
- by Nho, Byung Chul Dec 28, 2023 01:14pm
- Hugel, a global total medical aesthetics company, announced that it has held a board of directors meeting on the 22nd and passed a resolution to retire 371,563 shares of its own stock to enhance the shareholder’ value. This is equivalent to around 3% of the total outstanding shares (12,385,455 shares), and the expected value of the retired s
- Company
- Tezspire lands in Korea…joins 6-way race
- by Dec 28, 2023 06:02am
- The new drug for severe asthma that emerged joined the competition with the five existing biologics that were being used in Korea. AstraZeneca, which recently received domestic approval for its new drug, plans to differentiate itself from existing treatment options with new mechanisms of action and formulations. According to industry sources
- Company
- Acetaminophen syrup receives price hikes to meet demand
- by Chon, Seung-Hyun Dec 28, 2023 06:02am
- Starting next month, the maximum reimbursement prices for two acetaminophen suspension formulations will be increased by over 50%. The price hike follows the government’s decision to implement measures aimed at encouraging pharmaceutical companies to expand volume of acetaminophen production. Currently, there is a continuous demand for the drug
- Company
- Genexine completes trial on its long-acting anemia drug
- by Son, Hyung-Min Dec 28, 2023 06:02am
- Genexine’s new drug candidate for chronic kidney disease-induced anemia, Efesa, has confirmed its efficacy through clinical trials. Genexine plans to confirm the drug’s competitiveness in the oversaturated anemia treatment market with its long-acting formulation. According to the Financial Supervisory Service, Genexin recently announced tha
- Company
- KRW 250 bil market shakes from reimb reevaluations
- by Chon, Seung-Hyun Dec 28, 2023 06:02am
- The pharmaceutical industry has expressed great disappointment regarding the results of the government’s drug reimbursement reevaluations. The reimbursement scope of three ingredients - loxoprofen, limaprost alpha dex, and epinastine hydrochloride - will be reduced. This is a loss worth KRW 250 billion in the prescription market. The losses
